Ten flavonoid compounds isolated from the methanolic extract of a tropical weed plant, Chromolaena odorata leaves were tested against three multidrug-resistant (MDR) methicillin-resistant Staphylococcus aureus (MRSA) isolates with active efflux properties. Only low inhibitory potential were detected through the preliminary evaluation as indicated by their respective minimum inhibitory concentration (MIC) value. These results justify the need to conduct subsequent evaluation namely the efflux inhibitory potential assay. Ethidium bromide (EtBr) and reserpine were used as the standard efflux substrate and efflux inhibitor, respectively while S. aureus ATCC 25923 was used as the reference strain. Three flavonoid compounds namely eriodictyol-7,4'-dimethyl ether, naringenin-4'-methyl ether and 2'4-dihydroxy-4'5'6'-trimethoxychalcone showed high efflux inhibitory activity with four to eight fold reduction of EtBr MIC value, hence suggesting their potential to be develop into efflux inhibitors for MRSA.
INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA) are nosocomial-related, Gram-positive bacteria that have been known to display multidrug-resistant properties towards a wide range of structurally-unrelated antibiotics and antimicrobial agents. Apparently, these multidrug resistance traits are caused by an array of efflux pump/s in MRSA (Abulrob et al., 2004; Noguchi et al., 2005) . This novel mechanism has been identified as one of the main contributor of multidrug-resistance in S. aureus (Gibbons *Corresponding author. E-mail: saifulazmi@frim.gov.my. Tel: +603 6279 7346/7604. Fax: +603 6272 9805. et al., 2002; Horii et al., 2003) .
Chromolaena odorata (L.) R. King and H. Robinson (Asteraceae), formerly known as Eupatorium odoratum, is a perennial shrub widely known as serious pest and major weed plant in South East Asia, Africa and Pacific Islands. It spreads rapidly on lands used for forestry, pasture and plantation crops such as rubber, coffee, coconut, cocoa and cashew. It can reach a height of three meters in open situations and up to eight meters in the interior forests (IOBC, 2006) . Usually, compounds isolated from plants were evaluated using the disc diffusion technique or the minimum inhibition concentration (MIC) protocol for their anti-MRSA activity. Thus far, only a handful of fractionated phyto-compounds were identified as active antimicrobial agents. Studies have shown that the non-active fractions may contain potential efflux inhibitor (Guz et al., 2001; Stermitz et al., 2002) .
Previously, 11 flavonoid compounds have been isolated from this plant and eight of the flavonoids exhibited >50% inhibition on platelet-activating factor (PAF) receptor binding on rabbit platelets using 3 H-PAF as a ligand at 18.2 µg/ml (Ling et al., 2007) . Since previous reports have shown that this problematic plant exhibited antibacterial activity against opportunistic human pathogens (Irobi, 1992; Caceres et al., 1995) , in this study, two previously characterized multidrugresistant (MDR) MRSA clinical isolates and two ATCC reference strains with active efflux activity were used to evaluate the isolated flavonoid compounds from C. odorata.
MATERIALS AND METHODS

Plant material
Leaves of Chromolaena odorata were collected in July, 2003 from Kuang, Selangor Darul Ehsan, and identified by botanist of Forest Research Institute Malaysia (FRIM). A voucher specimen (FRI45415) was deposited in the Herbarium of FRIM. The leaves were dried in an oven at 40-45°C for 4 days.
Isolation of compounds
Compounds (1-9) were isolated from oven dried leaves (2 kg) of C. odorata as described previously (Ling et al., 2007) and as illustrated in Figure 1 . An additional flavonoid compound was also isolated in this study as follows; the methanol leaf extract (480 g) was suspended in distilled water and partitioned successively with hexane, chloroform and ethyl acetate to give the hexane (63 g), chloroform (148 g), ethyl acetate (60 g) and water (201 g) fractions. The chloroform fraction was dissolved in methanol and subjected to column chromatography using Sephadex LH-20 with methanol as the eluting solvent. The resulting eluents were separated into three sub-fractions (C1 to C3). Sub-fraction C1 (45 g) was chromatographed over silica gel column using chloroform and methanol (100:0→98:2) to yield three sub-fractions (C11 to C13). Sub-fraction C11 was further fractionated and purified using repeated column chromatography employing silica gel (hexane: ethyl acetate; 100:0→0:100 and chloroform: ethyl acetate; 100:0 →50:50) and Sephadex LH-20 (chloroform) to afford compound (10) (45.3 mg).
Identification of compounds
1 H-and 13 C-NMR spectra of the pure compounds were recorded in ppm (δ) in CD3OD, CDCl3 or DMSO-d6 with TMS as the internal standard, employing Bruker DRX 300 spectrometer operating at 300 MHz for 1 H, and 75 MHz for 13 C. The identities of compounds were confirmed by comparison of their 1 H-and 13 C-NMR data with literature values (Barua et al., 1978; Ling et al., 2007) .
Bacterial strains
The bacterial strains consisted of MRSA clinical isolates (N441 and U949) obtained from Hospital Universiti Kebangsaan Malaysia (HUKM) and two ATCC strains as references, namely the methicillin-sensitive S. aureus (MSSA) ATCC 25923 and MRSA ATCC 33591. Bacterial isolates were maintained on Protect Bacterial Preservers (Technical Service Consultants Limited, Heywood, Lancashire, England) and cultured in trypticase soy broth (TSB) at 37°C. Detailed identification, characterizat ion, antibiogram and active efflux properties of the S. aureus strains used in this study were published previously (Saiful et al., 2006 (Saiful et al., , 2008 .
Minimum inhibitory concentration (MIC) value determination assay
MIC assay were carried out as described previously (Mohtar et al., 2009) . All compounds were dissolved in dimethyl sulfoxide (DMSO) and MIC was determined in triplicate using double-broth microdillution method involving 96-well titre-plates. Additionally, the growth of the microorganisms was determined by adding 20 µL of thiazolyl blue tetrazolium (MTT) at 1 mg/ml and incubating for further 20 min. Clear-yellow wells indicated inhibition of the growth of organism, whilst dark-bluish coloured wells indicated absence of inhibition. The MIC value was defined as the lowest concentration producing no visible growth.
Efflux assay
Similar steps as the MIC value determination assay were followed with modifications as previously reported using a 96-well plate (Mastura et al., 2009) . For the positive control plate, a 0.5 McFarland standardized overnight cultures were inoculated into a Mueller-Hinton broth (MHB) containing serially-diluted ethidium bromide (EtBr), a universal efflux substrate for S. aureus. Following that, 50 µg/ml of reserpine, a common efflux inhibitor against S. aureus, was added. Active efflux was detected in an isolate if the MIC value of the tested efflux substrate (EtBr) added with an efflux inhibitor (reserpine) is lower than the MIC value of EtBr alone. Equivalently, in another plate, standardized 0.5 McFarland overnight cultures were also inoculated into MHB containing serially-diluted EtBr with the addition of each flavonoid compound at concentration of at least one fourth (1/4) of the MIC results. Consequently, potential efflux pump inhibitors were compounds that showed lower MIC value when added with EtBr than the MIC value of EtBr alone.
RESULTS
None of the 11 compounds (including reserpine) tested showed significant inhibitory action against S. aureus isolates with MIC > 250 µg/ml. For the efflux assay, N441 display a four-fold MIC value reduction while the other three isolates (U949, ATCC 33591 and ATCC 25923) exhibited two-fold reduction using the EtBr-reserpine combination as shown in Table 1 .
A total of three flavonoids; compounds 2, 4 and 10 displayed good potentiation of EtBr MIC value reduction as compared to reserpine. Compound 2 exhibited the best MIC value reduction of four and eight fold-reduction against all three MDR MRSA isolates. Additionally, both compounds 2 and 4 showed the highest potentiation of eight-fold and four-fold MIC value reduction against On the other hand, compounds 3, 5 and 6 showed a two-fold MIC value reduction against all three MRSA isolates while no change of MIC value against ATCC 25923 was observed. Both compounds 7 and 9 exhibited no change of MIC value against all of the test isolates. In addition, compounds 1 and 8 displayed only a two-fold potentiation against N441 and U949, respectively.
DISCUSSION
From a clinical perspective, a compound or plant extract that displays MIC value over 1 mg/ml, has little relevance since it is likely that a number of relatively inert substances may show antibacterial properties at this high concentration (Gibbons, 2004) . In addition, compound that exhibited MIC of more than 200 µg/ml is generally considered as a weak antibacterial agent and a potential source of efflux inhibitor (Stermitz et al., 2000; El-Deeb et al., 2003) .
Based on the efflux assay, all four isolates have active efflux activity, although the potentiation is quite low. Similar results were observed in other reports using the same EtBr-reserpine combinations (Mullin et al., 2004; Oluwatuyi et al., 2004) . Ethidium bromide, a common substrate for efflux pumps in MRSA strains was used to evaluate the presence of an active efflux activity (Abulrob et al., 2004; Oluwatuyi et al., 2004) . Reserpine on the other hand, is a well known potent inhibitor on both PMF dependent efflux system and the energy dependent, ATP-binding cassette (ABC) transporter system (Aeschlimann et al., 1999; Choudhuri et al., 2002) . To date, the EtBr-reserpine combination has been used internationally as a standard positive control for efflux activity in S. aureus (Stermitz et al., 2002; Oluwatuyi et al., 2004) .
As exemplified on Figure 1 , all of the remaining seven inactive flavonoids belong to the flavonol subclass based on their basic flavonoid skeleton structure which contains a hydroxyl substituent at position 3 of the C-ring. Studies have shown that either flavonolignans or flavonols which bore a free hydroxyl group at C3 were infective as inhibitors of the S. aureus efflux pumps (Guz et al., 2001; Stermitz et al., 2002) . These observations explain why all seven flavonols (compounds 1, 3, 5, 6, 7, 8 and 9) used in this study did not show efflux inhibitory activity against S. aureus.
In contrast, both compounds 2 and 4 belong to the subclass flavanone; which has no free hydroxyl group at C3 and double bond between C2 and C3. The absence of hydroxyl group in this compound might be responsible for the efflux inhibitory property as seen in this study. However, numerous studies have shown that the double bond between C2 and C3 plays an important role in the inhibition of various MDR efflux transporters thus suggesting that flavone, another subclass of flavonoid which has a double bond between C2 and C3 but lacks the hydroxyl group in C3 is the better candidate than flavanone for potential efflux inhibitor discovery (Zanden et al., 2004; Kitagawa et al., 2005) . Nevertheless, previous reports have also shown that the replacement of the flavone ring with flavanone did not mainly altered MDR modulating efficiency and flavanones does exert efflux inhibitory activity against several MDR efflux transporters (Ferte et al., 1999; Guz et al., 2001) . These studies suggest that the double bond between C2 and C3 is not significant in the inhibition of bacterial efflux system/s.
The second potential flavonoid-based efflux inhibitor from C. odorata is compound 10, which is grouped under the subclass chalcone that has an open C-ring. Chalcone has been reported to possess efflux inhibitory activity for several multidrug transporters and a methoxyl group on C4 on the chalcone structure will give higher inhibition (Pietro et al., 2002) ; as seen in compound 10. However, chalcone has been shown to be inactive against NorA but displays high affinity binding with P-glycoprotein efflux pump (Guz et al., 2001 ). Since S. aureus/MRSA has more than one active efflux pump working within the cell, chalcone may be suitable for other efflux protein besides NorA. The same study also suggests that the presence of a methoxyl group at C4 of the chalcone structure confer higher efflux inhibitory activity than a hydroxyl group on C4 (Guz et al., 2001) ; as seen in compound 10.
Interestingly, when all flavonoids used in this study are compared, all three of the potential efflux inhibitors; compounds 2, 4 and 10, has only two hydroxyl groups on the flavanone and chalcone structure respectively, while the other compounds has more than two hydroxyl groups on their structures (for example, both aromadendrin-4ʹ-methyl ether and kaempferol-4'-methyl ether has three hydroxyl groups). Previously, a study has reported similar finding where a flavonolignan having potent NorA efflux inhibitory activity has only two hydroxyl groups (Guz et al., 2001) . Difference in number and position of hydroxyl group in flavonoid molecules may play a role in the inhibition of efflux transporter, while increasing the number of hydroxyl group in the B ring decreases the efflux inhibitory effect (Sato et al., 2004; Kitagawa et al., 2005) . These studies support the role of chalcones and flavanones as a potential efflux pump inhibitor in S. aureus. Furthermore, all of the potential efflux inhibitors in this study are lipophilic compounds based on their R f values on the Thin Layer Chromatography (data not shown). Previous studies have also suggested that more lipophilic (or more hydrophobic) flavonoids could disrupt microbial membranes and subsequently inhibit the efflux pump system/s (Tsuchiya et al., 1996; Zloh and Gibbons, 2004) .
This preliminary study is the first to report on the potential efflux inhibitory activity of the flavonoid compounds isolated from C. odorata leaves against S. aureus efflux system/s. Generally, flavonoids that displayed efflux inhibition have only two hydroxyl groups on their chemical structures and do not bore a free hydroxyl group at C3 (for example, flavanone and chalcone). Additionally, the double bond between position C2 and C3 in flavonoids may not play an important role in S. aureus/MRSA efflux pump inhibition.
